Concerning Variants of SARS-CoV-2
The simultaneous emergence of different SARS-CoV-2 lineages from different countries around the world each carrying mutations in the spike protein receptor binding site reveal convergent selective pressure on SARS-CoV-2 to create an advantage towards its transmissibility and reinfection of individuals.
New Products for Coronavirus Research
Cayman’s SARS-CoV-2 (human) Neutralizing Recombinant Antibody disrupts the S1-RBD-ACE2 interaction and can be used for ELISA, immunofluorescence (IF), and Western blot (WB) applications. The antibody recognizes the SARS-CoV-2 spike glycoprotein at approximately 65 kDa.
Cayman’s ACE2 Polyclonal Antibody can be used for ELISA and Western blot (WB) applications. The antibody recognizes ACE2 at approximately 93 kDa from human and mouse samples.
Coronavirus Screening Tools
- Virtual library screening against SARS-CoV-2 targets
- Made-to-order compound library curated through in silico modeling by screening over 70,000 compounds targeting SARS-CoV-2 proteins
- Data package containing compound characteristics, docking scores, and predicted physicochemical properties for compound hits against nine SARS-CoV-2 targets
We also offer hit-to-lead and lead optimization services using in vitro/in vivo screening and a full suite of Structure-Based Drug Design services